In patients with allergic rhinitis and asthma, subcutaneous or sublingual AIT can shift the immune response from a Th2- to a Th1-dominated profile, decrease IgE production, and enhance the number and function of regulatory T cells (Tregs), thereby alleviating allergic inflammation. This evidence concerns the gene IGHE and allergic rhinitis.